Loading…

Anti-Prothrombin Antibodies and the Lupus Anticoagulant

The investigators have evaluated the frequency and manifestations of anti-prothrombin antibodies in patients with the lupus anticoagulant. Thirty-one of 42 patients with lupus anticoagulants associated with a variety of underlying conditions (74%) had evidence on crossed immunoelectrophoresis of ant...

Full description

Saved in:
Bibliographic Details
Published in:Blood 1988-08, Vol.72 (2), p.512-519
Main Authors: Fleck, Rebecca A., Rapaport, Samuel I., Rao, L. Vijaya Mohan
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c494t-19c4ea3f9830775ca02c22729f05ffea02cdd0778a2a94921b79791e27f279543
cites
container_end_page 519
container_issue 2
container_start_page 512
container_title Blood
container_volume 72
creator Fleck, Rebecca A.
Rapaport, Samuel I.
Rao, L. Vijaya Mohan
description The investigators have evaluated the frequency and manifestations of anti-prothrombin antibodies in patients with the lupus anticoagulant. Thirty-one of 42 patients with lupus anticoagulants associated with a variety of underlying conditions (74%) had evidence on crossed immunoelectrophoresis of anti-prothrombin antibodies. Twenty-four of 25 patients with an activated partial thromboplastin time exceeding 50 seconds and 14 of 15 patients with a prothrombin time exceeding control by more than two seconds had demonstrable anti-prothrombin antibodies. Three of the 31 patients with anti-prothrombin antibodies had essentially no measurable plasma prothrombin, a presumed result of accelerated clearance of prothrombin/ prothrombin antibody complexes. Each of these patients had bled abnormally. The remaining patients with antiprothrombin antibodies had neither substantial hypoprothrombinemia nor hemorrhagic manifestations, which confirms the non-neutralizing property of anti-prothrombin antibodies associated with the lupus anticoagulant. Since lupus anticoagulant immunoglobulins are known to react with phospholipids, the high prevalence of antibodies binding prothrombin led us to test the hypothesis of antibody polyreactivity. Adsorption of three lupus anticoagulant plasmas with insolubilized prothrombin markedly diminished evidence of both prothrombin/prothrombin antibody complexes and anticoagulant activity. Eluates of the insolubilized prothrombin contained IgG that not only bound prothrombin but possessed lupus anticoagulant activity. © 1988 by Grune & Stratton, Inc.
doi_str_mv 10.1182/blood.V72.2.512.512
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78347324</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497120810258</els_id><sourcerecordid>78347324</sourcerecordid><originalsourceid>FETCH-LOGICAL-c494t-19c4ea3f9830775ca02c22729f05ffea02cdd0778a2a94921b79791e27f279543</originalsourceid><addsrcrecordid>eNp9kD9PwzAQxS0EKqXwCRBSBsSWYl-cOh4Yqop_UiUYgNVyHJsaJXGxEyS-PU4bdWQ4nc7v3fnph9AlwXNCCrgta-eq-QeDOcxzsqsjNCU5FCnGgI_RFGO8SCln5BSdhfCFMaEZ5BM0AZovGGdTxJZtZ9NX77qNd01p22R4KF1ldUhkWyXdRifrftuHnaCc_Oxr2Xbn6MTIOuiLsc_Q-8P92-opXb88Pq-W61RRTruUcEW1zAwvMsxYriQGBcCAG5wbo4exqqJSSJCcciBlTMWJBmaA8ZxmM3Szv7v17rvXoRONDUrXMYN2fRCsyCjLYDBme6PyLgSvjdh620j_KwgWAy6xwyUiLgEiohoqbl2N5_uy0dVhZ-QT9etRl0HJ2njZKhsONsZY_L6Itru9TUcUP1Z7EZTVrdKV9Vp1onL23xh_5WmHjw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78347324</pqid></control><display><type>article</type><title>Anti-Prothrombin Antibodies and the Lupus Anticoagulant</title><source>ScienceDirect Journals</source><creator>Fleck, Rebecca A. ; Rapaport, Samuel I. ; Rao, L. Vijaya Mohan</creator><creatorcontrib>Fleck, Rebecca A. ; Rapaport, Samuel I. ; Rao, L. Vijaya Mohan</creatorcontrib><description>The investigators have evaluated the frequency and manifestations of anti-prothrombin antibodies in patients with the lupus anticoagulant. Thirty-one of 42 patients with lupus anticoagulants associated with a variety of underlying conditions (74%) had evidence on crossed immunoelectrophoresis of anti-prothrombin antibodies. Twenty-four of 25 patients with an activated partial thromboplastin time exceeding 50 seconds and 14 of 15 patients with a prothrombin time exceeding control by more than two seconds had demonstrable anti-prothrombin antibodies. Three of the 31 patients with anti-prothrombin antibodies had essentially no measurable plasma prothrombin, a presumed result of accelerated clearance of prothrombin/ prothrombin antibody complexes. Each of these patients had bled abnormally. The remaining patients with antiprothrombin antibodies had neither substantial hypoprothrombinemia nor hemorrhagic manifestations, which confirms the non-neutralizing property of anti-prothrombin antibodies associated with the lupus anticoagulant. Since lupus anticoagulant immunoglobulins are known to react with phospholipids, the high prevalence of antibodies binding prothrombin led us to test the hypothesis of antibody polyreactivity. Adsorption of three lupus anticoagulant plasmas with insolubilized prothrombin markedly diminished evidence of both prothrombin/prothrombin antibody complexes and anticoagulant activity. Eluates of the insolubilized prothrombin contained IgG that not only bound prothrombin but possessed lupus anticoagulant activity. © 1988 by Grune &amp; Stratton, Inc.</description><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood.V72.2.512.512</identifier><identifier>PMID: 2456797</identifier><language>eng</language><publisher>Washington, DC: Elsevier Inc</publisher><subject>Antibody Specificity ; Autoantibodies - analysis ; Biological and medical sciences ; Blood Coagulation Factors - analysis ; Blood Coagulation Factors - immunology ; Counterimmunoelectrophoresis ; Epitopes - analysis ; Hematologic and hematopoietic diseases ; Humans ; Lupus Coagulation Inhibitor ; Lupus Erythematosus, Systemic - immunology ; Medical sciences ; Platelet diseases and coagulopathies ; Prothrombin - immunology ; Prothrombin Time</subject><ispartof>Blood, 1988-08, Vol.72 (2), p.512-519</ispartof><rights>1988 American Society of Hematology</rights><rights>1988 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c494t-19c4ea3f9830775ca02c22729f05ffea02cdd0778a2a94921b79791e27f279543</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0006497120810258$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3549,27924,27925,45780</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=7773478$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2456797$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fleck, Rebecca A.</creatorcontrib><creatorcontrib>Rapaport, Samuel I.</creatorcontrib><creatorcontrib>Rao, L. Vijaya Mohan</creatorcontrib><title>Anti-Prothrombin Antibodies and the Lupus Anticoagulant</title><title>Blood</title><addtitle>Blood</addtitle><description>The investigators have evaluated the frequency and manifestations of anti-prothrombin antibodies in patients with the lupus anticoagulant. Thirty-one of 42 patients with lupus anticoagulants associated with a variety of underlying conditions (74%) had evidence on crossed immunoelectrophoresis of anti-prothrombin antibodies. Twenty-four of 25 patients with an activated partial thromboplastin time exceeding 50 seconds and 14 of 15 patients with a prothrombin time exceeding control by more than two seconds had demonstrable anti-prothrombin antibodies. Three of the 31 patients with anti-prothrombin antibodies had essentially no measurable plasma prothrombin, a presumed result of accelerated clearance of prothrombin/ prothrombin antibody complexes. Each of these patients had bled abnormally. The remaining patients with antiprothrombin antibodies had neither substantial hypoprothrombinemia nor hemorrhagic manifestations, which confirms the non-neutralizing property of anti-prothrombin antibodies associated with the lupus anticoagulant. Since lupus anticoagulant immunoglobulins are known to react with phospholipids, the high prevalence of antibodies binding prothrombin led us to test the hypothesis of antibody polyreactivity. Adsorption of three lupus anticoagulant plasmas with insolubilized prothrombin markedly diminished evidence of both prothrombin/prothrombin antibody complexes and anticoagulant activity. Eluates of the insolubilized prothrombin contained IgG that not only bound prothrombin but possessed lupus anticoagulant activity. © 1988 by Grune &amp; Stratton, Inc.</description><subject>Antibody Specificity</subject><subject>Autoantibodies - analysis</subject><subject>Biological and medical sciences</subject><subject>Blood Coagulation Factors - analysis</subject><subject>Blood Coagulation Factors - immunology</subject><subject>Counterimmunoelectrophoresis</subject><subject>Epitopes - analysis</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Humans</subject><subject>Lupus Coagulation Inhibitor</subject><subject>Lupus Erythematosus, Systemic - immunology</subject><subject>Medical sciences</subject><subject>Platelet diseases and coagulopathies</subject><subject>Prothrombin - immunology</subject><subject>Prothrombin Time</subject><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1988</creationdate><recordtype>article</recordtype><recordid>eNp9kD9PwzAQxS0EKqXwCRBSBsSWYl-cOh4Yqop_UiUYgNVyHJsaJXGxEyS-PU4bdWQ4nc7v3fnph9AlwXNCCrgta-eq-QeDOcxzsqsjNCU5FCnGgI_RFGO8SCln5BSdhfCFMaEZ5BM0AZovGGdTxJZtZ9NX77qNd01p22R4KF1ldUhkWyXdRifrftuHnaCc_Oxr2Xbn6MTIOuiLsc_Q-8P92-opXb88Pq-W61RRTruUcEW1zAwvMsxYriQGBcCAG5wbo4exqqJSSJCcciBlTMWJBmaA8ZxmM3Szv7v17rvXoRONDUrXMYN2fRCsyCjLYDBme6PyLgSvjdh620j_KwgWAy6xwyUiLgEiohoqbl2N5_uy0dVhZ-QT9etRl0HJ2njZKhsONsZY_L6Itru9TUcUP1Z7EZTVrdKV9Vp1onL23xh_5WmHjw</recordid><startdate>19880801</startdate><enddate>19880801</enddate><creator>Fleck, Rebecca A.</creator><creator>Rapaport, Samuel I.</creator><creator>Rao, L. Vijaya Mohan</creator><general>Elsevier Inc</general><general>The Americain Society of Hematology</general><scope>6I.</scope><scope>AAFTH</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19880801</creationdate><title>Anti-Prothrombin Antibodies and the Lupus Anticoagulant</title><author>Fleck, Rebecca A. ; Rapaport, Samuel I. ; Rao, L. Vijaya Mohan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c494t-19c4ea3f9830775ca02c22729f05ffea02cdd0778a2a94921b79791e27f279543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1988</creationdate><topic>Antibody Specificity</topic><topic>Autoantibodies - analysis</topic><topic>Biological and medical sciences</topic><topic>Blood Coagulation Factors - analysis</topic><topic>Blood Coagulation Factors - immunology</topic><topic>Counterimmunoelectrophoresis</topic><topic>Epitopes - analysis</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Humans</topic><topic>Lupus Coagulation Inhibitor</topic><topic>Lupus Erythematosus, Systemic - immunology</topic><topic>Medical sciences</topic><topic>Platelet diseases and coagulopathies</topic><topic>Prothrombin - immunology</topic><topic>Prothrombin Time</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fleck, Rebecca A.</creatorcontrib><creatorcontrib>Rapaport, Samuel I.</creatorcontrib><creatorcontrib>Rao, L. Vijaya Mohan</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fleck, Rebecca A.</au><au>Rapaport, Samuel I.</au><au>Rao, L. Vijaya Mohan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anti-Prothrombin Antibodies and the Lupus Anticoagulant</atitle><jtitle>Blood</jtitle><addtitle>Blood</addtitle><date>1988-08-01</date><risdate>1988</risdate><volume>72</volume><issue>2</issue><spage>512</spage><epage>519</epage><pages>512-519</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><abstract>The investigators have evaluated the frequency and manifestations of anti-prothrombin antibodies in patients with the lupus anticoagulant. Thirty-one of 42 patients with lupus anticoagulants associated with a variety of underlying conditions (74%) had evidence on crossed immunoelectrophoresis of anti-prothrombin antibodies. Twenty-four of 25 patients with an activated partial thromboplastin time exceeding 50 seconds and 14 of 15 patients with a prothrombin time exceeding control by more than two seconds had demonstrable anti-prothrombin antibodies. Three of the 31 patients with anti-prothrombin antibodies had essentially no measurable plasma prothrombin, a presumed result of accelerated clearance of prothrombin/ prothrombin antibody complexes. Each of these patients had bled abnormally. The remaining patients with antiprothrombin antibodies had neither substantial hypoprothrombinemia nor hemorrhagic manifestations, which confirms the non-neutralizing property of anti-prothrombin antibodies associated with the lupus anticoagulant. Since lupus anticoagulant immunoglobulins are known to react with phospholipids, the high prevalence of antibodies binding prothrombin led us to test the hypothesis of antibody polyreactivity. Adsorption of three lupus anticoagulant plasmas with insolubilized prothrombin markedly diminished evidence of both prothrombin/prothrombin antibody complexes and anticoagulant activity. Eluates of the insolubilized prothrombin contained IgG that not only bound prothrombin but possessed lupus anticoagulant activity. © 1988 by Grune &amp; Stratton, Inc.</abstract><cop>Washington, DC</cop><pub>Elsevier Inc</pub><pmid>2456797</pmid><doi>10.1182/blood.V72.2.512.512</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0006-4971
ispartof Blood, 1988-08, Vol.72 (2), p.512-519
issn 0006-4971
1528-0020
language eng
recordid cdi_proquest_miscellaneous_78347324
source ScienceDirect Journals
subjects Antibody Specificity
Autoantibodies - analysis
Biological and medical sciences
Blood Coagulation Factors - analysis
Blood Coagulation Factors - immunology
Counterimmunoelectrophoresis
Epitopes - analysis
Hematologic and hematopoietic diseases
Humans
Lupus Coagulation Inhibitor
Lupus Erythematosus, Systemic - immunology
Medical sciences
Platelet diseases and coagulopathies
Prothrombin - immunology
Prothrombin Time
title Anti-Prothrombin Antibodies and the Lupus Anticoagulant
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T15%3A04%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anti-Prothrombin%20Antibodies%20and%20the%20Lupus%20Anticoagulant&rft.jtitle=Blood&rft.au=Fleck,%20Rebecca%20A.&rft.date=1988-08-01&rft.volume=72&rft.issue=2&rft.spage=512&rft.epage=519&rft.pages=512-519&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood.V72.2.512.512&rft_dat=%3Cproquest_cross%3E78347324%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c494t-19c4ea3f9830775ca02c22729f05ffea02cdd0778a2a94921b79791e27f279543%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=78347324&rft_id=info:pmid/2456797&rfr_iscdi=true